Oleg Nodelman
Fortuna: - $ al 31/07/2026
Fortuna: - $ al 31/07/2026
Mr. Oleg Nodelman is an Independent Director at Zymeworks, Inc., an Independent Director at AnaptysBio, Inc., a Founder & Portfolio Manager at EcoR1 Capital, LLC, a Chief Executive Officer at EcoR1 Panacea Holdings LLC and a Founder and Portfolio Manager at Ecor1 Capital LLC /Venture Capital/.
He is on the Board of Directors at Zymeworks, Inc., Lakefront Biotherapeutics, AnaptysBio, Inc., Paratus Sciences Corp., ReCode Therapeutics, Inc. and Scorpion Therapeutics, Inc. Mr. Nodelman was previously employed as an Independent Director by Nuvation Bio, Inc., a Chairman & Chief Executive Officer by Panacea Acquisition Corp., a Chairman & Chief Executive Officer by Panacea Acquisition Corp.
II, an Independent Director by Prothena Corp.
Plc, a Non-Executive Director by Addex Therapeutics Ltd., a Portfolio Manager by Biotechnology Value Fund LP, and a Portfolio Manager by BVF Partners LP.
He also served on the board at Aktis Oncology, Inc. He received his undergraduate degree from Georgetown University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
AKTIS ONCOLOGY, INC. -.--% | 12/01/2026 | 0 ( -.--% ) | - $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ANAPTYSBIO, INC. | Director/Miembro de la Junta | 08/04/2021 |
| LAKEFRONT BIOTHERAPEUTICS NV | Director/Miembro de la Junta | 07/10/2024 |
| ZYMEWORKS INC. | Director/Miembro de la Junta | 17/02/2025 |
Paratus Sciences Corp.
Paratus Sciences Corp. BiotechnologyHealth Technology Operates as a biotechnology company | Director/Miembro de la Junta | - |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage genetic medicines company that develops therapeutics for genetically defined diseases | Director/Miembro de la Junta | - |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops precision oncology therapies for cancer treatment | Director/Miembro de la Junta | - |
EcoR1 Panacea Holdings LLC | Director Ejecutivo | - |
EcoR1 Capital, LLC
EcoR1 Capital, LLC Investment ManagersFinance EcoR1 invests (long and short) in securities, consisting principally, but not solely, of equity and equity-related securities that are issued by biotechnology companies globally. | Director Ejecutivo | 01/01/2012 |
| Empresas | Cargo | Fin |
|---|---|---|
| AKTIS ONCOLOGY, INC. | Director/Miembro de la Junta | 20/05/2026 |
| ░░░░░░░░ ░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░ ░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░ ░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░ ░░░░░ ░░ | ░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░ ░░░░░ | ░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 17 |
|---|---|
Biotechnology Value Fund LP
Biotechnology Value Fund LP Investment Trusts/Mutual FundsMiscellaneous Functions as a hedge fund | Miscellaneous |
BVF Partners LP
BVF Partners LP Investment ManagersFinance BVF generally pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The focus of the BVF strategy is on fundamental, bottom-up analysis of individual issuers based on the theory that market mispricing exist because market prices do not incorporate all knowable economic and other relevant data. | Finance |
Galapagos NV
Galapagos NV BiotechnologyHealth Technology Manufactures and develops pharmaceutical products for oncology | Health Technology |
AnaptysBio, Inc.
AnaptysBio, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company | Health Technology |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Addex Therapeutics Ltd.
Addex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs | Health Technology |
Prothena Corp. Plc
Prothena Corp. Plc BiotechnologyHealth Technology Focuses on the discovery and development of novel antibodies | Health Technology |
EcoR1 Capital, LLC
EcoR1 Capital, LLC Investment ManagersFinance EcoR1 invests (long and short) in securities, consisting principally, but not solely, of equity and equity-related securities that are issued by biotechnology companies globally. | Finance |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage genetic medicines company that develops therapeutics for genetically defined diseases | Health Technology |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops precision oncology therapies for cancer treatment | Health Technology |
Panacea Acquisition Corp.
Panacea Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
EcoR1 Panacea Holdings LLC | |
Nuvation Bio, Inc.
Nuvation Bio, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops oncology related novel therapeutic candidates | Health Technology |
Panacea Acquisition Corp. II
Panacea Acquisition Corp. II Financial ConglomeratesFinance Operates as a blank check company | Finance |
Aktis Oncology, Inc.
Aktis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops and discovers radiopharmaceuticals to treat tumor cancers | Health Technology |
Paratus Sciences Corp.
Paratus Sciences Corp. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Zymeworks, Inc.
Zymeworks, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.